Phase 4 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been recently diagnosed with persistent atrial fibrillation (an irregular heart rhythm that doesn't stop on its own) that is causing symptoms, diagnosed no more than 6 months before joining the trial
- People aged 18 or older
- People with a body mass index (BMI) of 30 or above, OR a BMI of 27 or above combined with at least one weight-related health condition such as high blood pressure, high cholesterol, sleep apnea, or heart disease
- People who are already scheduled for an electrical cardioversion (a procedure that uses a controlled electric shock to restore normal heart rhythm)
- People who are willing and able to provide written consent to participate
Who may not be able to join:
- People with permanent atrial fibrillation (where the irregular heart rhythm is long-lasting and not being treated with cardioversion)
- People whose atrial fibrillation is caused by another medical condition, such as a thyroid problem, an infection like pneumonia, or recent heart or chest surgery
- People who are currently taking or have previously taken the heart medication amiodarone
- People whose blood sugar control test (HbA1c) result was at or above a certain level within the 3 months before joining (confirm with trial site)
- People with a history of type 1 or type 2 diabetes
- People who have previously had weight-loss (bariatric) surgery
- People who have used other weight-loss medications within the 3 months before joining
- People who have a medical reason not to use a type of medication called a GLP-1 receptor agonist, or who have used one before
- People with a history of long-term pancreatitis, or who have had a sudden pancreatitis episode within the past 6 months
- People who have had a heart attack or acute coronary event within the past 6 months
- People with severe heart valve disease
- People with significantly reduced kidney function (confirm with trial site)
- People with severe heart failure that considerably limits physical activity
- People who have taken part in another clinical drug or device trial within the past 30 days (participation in a registry is allowed)
- People whose treating doctor considers them unsuitable for the trial for any reason, including a life expectancy of less than 12 months
- People who are pregnant, breastfeeding, planning to become pregnant, or who are able to become pregnant and are not using a highly effective form of contraception
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ron Pisters, dr., Rijnstate Hospital
Phone: +31650818296
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.